MP Healthcare Venture Management

Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

Sola Bio develops a modular bioreactor called Sola that empowers people to grow cells.

LiberoThera Co., Ltd. engages in the discovery of drugs targeting on membrane proteins for the medical care industry. It also offers drug discovery services. The company was founded in 2018 and is based in Tokyo, Japan.

Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper, are the essential ingredient in these metalloenzymes.

Korro Bio Inc. specializes in the development of nucleic acid-based therapeutics aimed at targeting specific sequences in genetic code, with a focus on treating rare diseases. Founded in 2018 and located in Cambridge, Massachusetts, the company utilizes a proprietary platform that enables efficient and selective RNA editing by leveraging natural processes found in multi-cellular organisms. This innovative approach allows Korro Bio to edit messenger RNA and recode specific codons, facilitating targeted modifications in protein structure and function across various tissues.

QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Sonde Health is a digital medicine company developing voice-based technologies to transform the way we monitor and diagnose our mental and physical health.

QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

QurAlis Corporation is a biotechnology company focused on discovering and developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurological diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis aims to address the genetic underpinnings of ALS, leveraging its proprietary platforms and biomarkers to create targeted treatments. The company's pipeline includes innovative therapies designed to restore dysfunctional cellular processes, treat overactive neurons, and eliminate toxic proteins associated with the disease. By concentrating on genetically validated targets, QurAlis seeks to advance antisense oligonucleotides and small molecule programs that can effectively manage various subtypes of ALS, ultimately working to halt disease progression and improve patient outcomes. QurAlis operates as a subsidiary of Q-State Biosciences, Inc.

Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.

Forge Therapeutics, Inc is a biotechnology company discovering and developing novel therapeutics using an innovative chemistry platform targeting metalloproteins. Forge uses a proprietary approach combining bioinorganic (study of metals in biology) and medicinal chemistry to generate selective inhibitors of this large class of targets.

Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.

MiRagen is a biopharmaceutical company that discovers and develops innovative microRNA-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. The company was founded in 2007 and headquartered in Boulder, Colorado.

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Thrasos is a bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's lead therapeutic program, THR-184, is focused on the prevention and treatment of acute kidney injury (AKI). The Company also has a preclinical development program for treating chronic kidney disease (CKD).

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

PharmEste s.r.l., a biopharmaceutical company, engages in the discovery and development of transient receptor potential (TRP) channel therapeutics for the treatment of neuropathic pain, overactive bladder, and other TRP-mediated diseases. It develops PHE377, a TRPV1 antagonist for the treatment of neuropathic pain.

Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage. Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company develops tetravalent bispecific antibodies for cancer therapy. Its medicines used in immuno-oncology treatments. The company plans for the initiation of a Phase I, open label, first-in-human clinical study of FS222, a bispecific antibody targeting CD137 (4-1BB) and PD-L1. The company is based in Cambridge, the United Kingdom.

Genocea Biosciences, Inc. is a biopharmaceutical company specializing in the discovery and development of innovative cancer immunotherapies and vaccines to address significant unmet medical needs. Based in Cambridge, Massachusetts, the company utilizes its proprietary ATLAS platform to profile patients' CD4+ and CD8+ T cell immune responses to identify potential targets within their tumors. Genocea's key programs include GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine initiative. The company also develops immunotherapies for other conditions, such as GEN-003, which targets genital herpes, and maintains pre-clinical programs focused on personalized cancer vaccines. Through its AnTigen Lead Acquisition System, Genocea is committed to advancing vaccine and immunotherapy solutions for various diseases.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Covagen develops bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy. Their goal is to access novel biology for each product candidate. Covagen’s lead FynomAb COVA322 is being developed for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis. In October 2012 Covagen entered into a strategic research collaboration and license agreement with Mitsubishi Tanabe / TRL for the development of bispecific FynomAbs against target pairs selected by Mitsubishi Tanabe / TRL. Covagen was founded in 2007 as a spin-off company from ETH Zurich (Swiss Federal Institute of Technology). A strong syndicate of investors supports Covagen’s drug development programs including Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Private biotechnology company that develops systematic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. The company's expertise in drug development and delivery serves as the foundation of Intradigm RNAi platform. In particular, the company proprietary RNAi Nanoplex delivery technology is unique in its ability to enable the targeted delivery of RNAi therapeutics to specific tissues through systemic administration of the drug product.